Remove Communication Remove Drug Development Remove White Paper
article thumbnail

MD Anderson and Xilis partner to expedite new cancer therapies development

Pharmaceutical Technology

It may offer opportunities for third-party collaborations to guide the new cell therapies and drugs development, if successful. It enables quick evaluation of a patient tumour response to a range of cancer drug modalities within 14 days of obtaining harvested samples of tumour cells.

article thumbnail

FDA suggests ways to curb constraints with rare disease gene therapy trials

Pharmaceutical Technology

Despite the challenges that drug developers must overcome to produce gene therapies for rare diseases, Hart underscored the FDA’s intent to encourage more innovation in this space. “We Therefore, the good news is we have flexibilities that can be offered to see drug development for these diseases.”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

AbbVie and Capsida partner for gene therapies to treat eye diseases

Pharmaceutical Technology

Combining AbbVie’s expertise in eye disease drug development and commercialisation with Capsida’s fully integrated next-generation AAV engineering platform and manufacturing capabilities offers the potential to provide novel therapies enabling unprecedented benefit to patients with serious eye diseases.”

article thumbnail

Solid Biosciences partners with Phlox for cardiac disease therapies

Pharmaceutical Technology

Under the research partnership deal, the companies will develop new precision genetic medicines for a severe form of genetic dilated cardiomyopathy (DCM). Solid Biosciences stated that the partnership boosts its scientific capabilities along with commercial potential in cardiac therapy.

article thumbnail

Race to the finish: pharma edges closer to approval with RSV vaccines

Pharmaceutical Technology

Pharmaceutical companies are pushing to develop drugs and vaccines for RSV with these populations in mind. Since the FDA approved AstraZeneca’s monoclonal antibody therapy Synagis (palivizumab) 25 years ago, drug development successes for RSV have been few and far between.

article thumbnail

NHC Comments on IRA Guidance Response

Putting Patients First Blog

10: External Data Submission Timing The NHC understands the tight timeline for the drug selection and price negotiation processes. As discussed in the NHC’s 2020 white paper on the topic,3 patient value is multi-faceted, and any attempts to distill important dimensions of patient value and benefit into a single number is fraught.

article thumbnail

The Important Role that Biopharmaceutics Plays in Accelerating Early-Phase Drug Development

Pharmaceutical Technology

As formulators, we are often able to directly impact the amount of drug absorbed through formulation optimization and improve exposure. However, the chances of improving the exposure profile of a drug that is highly cleared by formulation modification are limited. Please check your email to download the Whitepaper.